In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB)

Vaccine

Volumn 27, Issue 20, 2009, Pages 2662-2668

  Knowles, M Kimberly ^a   Roberts, Danielle ^a   Craig, Sheona ^a   Sheen, Mary ^a   Nadin Davis, Susan A ^a   Wandeler, Alexander I ^a  

^a CANADIAN FOOD INSPECTION AGENCY   (Canada)

Author keywords

Adenovirus; Oral vaccine; Rabies glycoprotein; Recombinant virus stability

Indexed keywords

EPITOPE; HUMAN ADENOVIRUS 5 RABIES GLYCOPROTEIN RECOMBINANT VACCINE; MONOCLONAL ANTIBODY; ONRAB; RABIES VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CLONING; CONTROLLED STUDY; COTTON RAT; CYTOPATHOGENIC EFFECT; DRUG ADMINISTRATION ROUTE; FLUORESCENT ANTIBODY TECHNIQUE; GENE INSERTION; GENETIC STABILITY; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES; REAL TIME POLYMERASE CHAIN REACTION; WILDLIFE RABIES;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; DNA, VIRAL; DRUG STABILITY; EPITOPES; MICE; RABIES; RABIES VACCINES; SEQUENCE ANALYSIS, DNA; SIGMODONTINAE; VACCINES, SYNTHETIC;

EID: 64449087790     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.074     Document Type: Article

References (33)

1. MacInnes C.D., Smith S.M., Tinline R.R., Ayers N.R., Bachmann P., Ball D.G.A., et al. Elimination of rabies from red foxes in Eastern Ontario. J Wildl Dis 37 (2001) 119-132
2. Fehlner-Gardiner C., Nadin-Davis S., Armstrong J., Muldoon F., Bachmann P., and Wandeler A. ERA vaccine-derived cases of rabies in wildlife and domestic animals in Ontario, Canada, 1989-2004. J Wildl Dis 44 (2008) 71-85
3. Bern. Vaccine 12 (1994) 317-320
4. Rupprecht C.E., Charlton K.M., Artois M., Casey G.A., Webster W.A., Campbell J.B., et al. Ineffectiveness and comparative pathogenicity of attenuated rabies virus vaccines for the striped skunk (Mephitis mephitis). J Wildl Dis 26 (1990) 99-102
5. Rupprecht C.E., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H., et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA 83 (1986) 947-950
6. Kieny M.P., Lathe R., Drillien R., Spehner D., Skory S., Schmitt D., et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 312 (1984) 163-166
7. Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 354 (1991) 520-522
8. Hanlon C.A., Niezgoda M., Hamir A.N., Schumacher C., Koprowski H., and Rupprecht R. First North American field release of a vaccinia-rabies glycoprotein recombinant virus. J Wildl Dis 34 (1998) 228-239
9. Rosatte R., Donovan D., Allan M., Howes L.A., Silver A., Bennett K., et al. Emergency response to raccoon rabies introduction into Ontario. J Wildl Dis 37 (2001) 265-279
10. Tolson N.D., Charlton K.M., Stewart R.B., Campbell J.B., and Wiktor T.J. Immune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. Can J Vet Res 51 (1987) 363-366
11. Grosenbaugh D.A., Maki J.L., Rupprecht C.E., and Wall D.K. Rabies challenge of captive striped skunks (Mephitis mephitis) following oral administration of a live vaccinia-vectored rabies vaccine. J Wildl Dis 43 (2007) 124-128
12. Shenk T.E. Adenoviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields virology. 3rd edition (1996), Lippincott-Raven Publishers, Philadelphia 2265-2300
13. Graham F.L., and Prevec L. Adenovirus-based expression vectors and recombinant vaccines. In: Ellis R.W. (Ed). Vaccines: new approaches to immunological problems (1992), Butterworth-Heinemann, Boston 363-390
14. Prevec L., Campbell J.B., Christie B.S., Belbeck L., and Graham F.L. A recombinant human adenovirus vaccine against rabies. J Infect Dis 161 (1990) 27-30
15. Yarosh O.K., Wandeler A.I., Graham F.L., Campbell J.B., and Prevec L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 14 (1996) 1257-1264
16. Amexis G., Oeth P., Abel K., Ivshina A., Peloquin F., Cantor C.R., et al. Quantitative mutant analysis of viral quasispecies by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98 (2001) 12097-12102
17. Hansen H., Okeke M.I., Nilssen O., and Traavik T. Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene. Vaccine 23 (2004) 499-506
18. Laassri M., Meseda C.A., Williams O., Merchlinsky M., Weir J.P., and Chumakov K. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene. J Med Virol 79 (2007) 791-802
19. Lutze-Wallace C., Sapp T., Sidhu M., and Wandeler A. In vitro assessments of the genetic stability of a live recombinant human adenovirus vaccine against rabies. Can J Vet Res 59 (1995) 157-160
20. Lutze-Wallace C., Wandeler A., Prevec L., Sidhu M., Sapp T., and Armstrong J. Characterization of a Human Adenovirus 5: rabies glycoprotein recombinant vaccine reisolated from orally vaccinated Skunks. Biologicals 23 (1995) 271-277
21. Pacini D.L., Dubovi E.J., and Clyde Jr. W.A. A new animal model for human and respiratory tract disease due to adenovirus. J Infect Dis 150 (1984) 92-97
22. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 (1997) 59-72
23. Elmgren, L.D., 1999. Epitope mapping of lyssavirus structural proteins. Ph.D. Thesis. University of Ottawa, Ottawa, Ontario, Canada.
24. Lorenz R.J., and Bogel K. Methods of calculation. In: Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies. 3rd edition (1973), World Health Organization, Geneva 321-335
25. Chroboczek J., Bieber F., and Jacrot B. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186 (1992) 280-285
26. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucl Acids Res 25 (1997) 4876-4882
27. Prince G.A., Porter D.D., Jenson A.B., Horswood R.L., Chanock R.M., and Ginsberg H.S. Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). J Virol 67 (1993) 101-111
28. Dietzschold M.L., Faber M., Mattis J.A., Pak K.Y., Schnell M.J., and Dietzschold B. In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. Vaccine 23 (2004) 518-524
29. Anilionis A., Wunner W.H., and Curtis P.J. Structure of the glycoprotein gene in rabies virus. Nature 294 (1981) 275-278
30. Wiktor T.J., MacFarlan R.I., Reagan K.J., Dietzschold B., Curtis P.J., Wunner W.H., et al. Protection from rabies by a vaccinia recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 81 (1984) 7194-7198
31. Bett A.J., Prevec L., and Graham F.L. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67 (1993) 5911-5921
32. Youil R., Toner T.J., Su Q., Casimiro D., Shiver J.W., Chen L., et al. Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region of growth properties of first-generation adenoviruses. Hum Gene Ther 14 (2003) 1017-1034
33. Burgert H.-G., and Blusch J.H. Immunomodulatory functions encoded by the E3 transcription unit of Adenoviruses. Virus Genes 21 (2000) 13-25